ReviewDiscover oncology2025
Characterization and treatment of brain metastases from pancreatic cancer: a systematic review.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBrain metastases (BM) from pancreatic cancer have low incidence, carry a poor prognosis, and have limited treatment options. Summarizing disease features and treatment protocols can help understand and improve prognosis.
methodsRegistered with INPLASY and following PRISMA guidelines, the study searched PubMed, Embase, Scopus, and Web of Science from database inception to 9th January 2025. The Kaplan-Meier method was used to calculate the median survival time and interquartile range (IQR) of Overall Survival (OS), and the corresponding plot was drawn.
resultsA total of 614 patients with BM from pancreatic cancer were included, originating from 24 case reports & series and 3 retrospective cohort studies. BM was usually multiple (n = 32, 71.1%), and mostly affecting frontal lobes (n = 30, 23.8%). Radiotherapy was primary treatment for BM in both pancreatic surgical (n = 44, 72.1%) and non-surgical (n = 8, 66.7%) groups, and most patients in the non-surgical group underwent chemotherapy and targeted therapy (41.7% vs 6.6%). Patients who underwent pancreatic surgery, had longer time from diagnosis of pancreatic cancer to BM (median: 24.0 vs 11.9 months) but shorter post-BM survival [median: 6.0 (case report/series), 3.0 (retrospective cohort study) vs 10.0 months].
conclusionThis review covers the characteristics, treatment, and prognosis of patients with BM from pancreatic cancer. Radiotherapy may be considered the primary treatment for BM, and pancreatic surgery may impact treatment and prognosis. Large multicenter studies are needed in view of low BM incidence from pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.